Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02682992 · ClinicalTrials.gov registry record · NA
Low-Level Laser Therapy for Prevention of Oral Mucositis
A NA study, sponsored by David A. Clump, MD, PhD.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT02682992: Completed NA study, sponsored by David A. Clump, MD, PhD.
NCT02682992 is a NA study that has completed, run by David A. Clump, MD, PhD. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02682992, a NA study, has completed, sponsored by David A. Clump, MD, PhD.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The overall purpose of this study is to examine the efficacy of prophylactic low-level laser therapy (LLLT) to reduce the incidence of oral mucositis and adverse events in patients receiving combined modality therapy consisting of chemotherapy and radiation therapy for head and neck cancer.
Primary Outcome
Percentage of participants with severe oral mucositis per the World Health Organization (WHO grade 3-4) (ulcerative lesions of the oral mucosa) in patients treated to a cumulative radiation dose of at least 5000 cGy.
Interventions
- DEVICE Low Level Laser Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-11 |
| Phase | NA |
What the finished NCT02682992 record still lists
NCT02682992 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Low Level Laser Therapy is the first listed.
NCT02682992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02682992 about?
NCT02682992 is a clinical study titled "Low-Level Laser Therapy for Prevention of Oral Mucositis". The overall purpose of this study is to examine the efficacy of prophylactic low-level laser therapy (LLLT) to reduce the incidence of oral mucositis and adverse events in patients receiving combined modality therapy consisting of chemotherapy and radiation therapy for head and neck cancer.
What is the current status of trial NCT02682992?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2016-06. Estimated completion is 2020-11.
What interventions are being tested in trial NCT02682992?
The interventions under investigation include: Low Level Laser Therapy (DEVICE).
Who is sponsoring clinical trial NCT02682992?
This trial is sponsored by David A. Clump, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02682992's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia